1 / 5

* ongoing lines of GVHD treatment in the monitored timeframe

Table 1: Clinical characteristics of patients with Acute GVHD.

conley
Download Presentation

* ongoing lines of GVHD treatment in the monitored timeframe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Table 1: Clinical characteristics of patients with Acute GVHD NHL= Non-Hodgkin’s Lymphoma, CLL= Chronic Lymphocytic Leukemia, ALL= Acute Lymphoblastic Leukemia, AML= Acute Myeloblastic Leukemia, MPS= Mucopolysaccaridosis, HLH= Hemophagocytic Lymphohistiocytosis, FLU= Fludarabine, TT= Thiotepa, CY=Cyclophosphamide, TBI= Total Body Irradiation, VP-16= Etoposide, TREO= Treosulfan, BU= Busulfan, SIB= Sibling, URD= Matched Unrelated Donor, UCB= Umbilical Cord Blood, CSA= Cyclosporine A, MTX= Methotrexate, ATG= Anti-Thymocyte Globulin, PDN= Prednisone. *ongoing lines of GVHD treatment in the monitored timeframe

  2. Table 2: Clinical characteristics of patients with Chronic GVHD ALL= Acute Lymphoblastic Leukemia, AML= Acute Myeloblastic Leukemia, CML= Chronic Myelocytic Leukemia, THAL= Thalassemia, NHL= Non-Hodgkin’s Lymphoma, TBI= Total Body Irradiation, VP-16= Etoposide, CY= Cyclophosphamide, FLU= Fludarabine, MEL= Melphalan, BU= Busulfan, TREO= Treosulfan, ATG= Anti-Thymocyte Globulin, TT= Thiotepa, URD= Matched Unrelated Donor, FAM= Familiar Donor, SIB= Sibling, HAPLO= Haploidentical, CSA= Cyclosporine A, MTX= Methotrexate, PDN= Prednisone. *ongoing lines of GVHD treatment in the monitored timeframe

  3. Table 3: Clinical characteristics of patients without GVHD Patient No. (UPN) and sex Age at allogeneic HSCT (years) Diagnosis Conditioning regimens Sex disparity Donor Prophylaxis/Treatment before GVHD onset Lines of GVHD treatment* 1/F 11 SAA CY yes SIB CSA, MTX 0 2/F 5 SAA BU, CY, MEL yes SIB FK 506 0 3/M 7 ALL TBI, VP-16, CY no SIB CSA 1 BU, CY, MEL 4/M 13 AML no URD CSA, MTX, ATG 1 BU, CY, MEL 5/M 14 MDS no URD CSA, MTX, ATG 5 BU, CY, MEL 6/M 1 JMML no SIB CSA, MTX, ATG 0 7/ M 9 ALL TBI, VP-16 yes URD ATG 4 8/M 15 ALL TBI, CY no URD CSA, MTX, ATG 1 BU, CY, MEL 9/F 11 MDS yes URD CSA, MTX, ATG 0 10/M 61 Myeloma TBI no SIB CY, MTX 1 11/M 45 AML BU, FLU no SIB CY, MTX 0 12/M 14 ALL TBI, VP-16 no SIB CSA, MTX, ATG 0 13/M 39 ALL TBI, CY yes URD CY, MTX 1 14/M 68 AML BU, CY no SIB CSA, MTX 1 15/M 22 ALL TBI, CY no URD CSA, MTX, ATG 1 16/M 50 ALL TBI, CY no SIB CSA, MTX, 1 BU, MEL 17/M 59 Myeloma no SIB CSA, MTX, 0 yes 18/F 51 AML URD CSA 2 BU, CY, ATG yes 19/M 55 AML BU, CY SIB CSA, MTX 0 SAA= Severe Aplastic Anaemia, ALL= Acute Lymphoblastic Leukemia,AML= Acute Myeloblastic Leukemia, MDS= Myelodysplastic Syndromes, JMML= Juvenile Myelomonocytic Leukemia, CY=Cyclophosphamide, TBI= Total Body Irradiation, BU= Busulfan, MEL= Melphalan, VP-16= Etoposide, FLU= Fludarabine, ATG= Anti-Thymocyte Globulin, SIB= Sibling, URD= Matched Unrelated Donor, CSA= Cyclosporine A, MTX= Methotrexate. *ongoing lines of GVHD treatment in the monitored timeframe

More Related